Warren Jr Biography and Net Worth



Warren G. Nighan joined AngioDynamics as the Senior Vice President of Quality and Regulatory Affairs in April 2017. Before joining AngioDynamics, Mr. Nighan was as a quality and regulatory consultant to clients in FDA-regulated industries, specializing in execution and management of quality systems implementation and remediation. Previously, Mr. Nighan served as the Executive Vice President of Global Clinical, Quality Affairs and Regulatory Affairs at Haemonetics Corporation, Vice President of Quality/Regulatory/Clinical/Technical Services at St. Jude Medical’s Atrial Fibrillation Division, and Corporate Vice President of Quality/Compliance at Tyco Healthcare/Covidien (Medtronic). Mr. Nighan earned a Bachelor and Master of Science in Nursing from Northeastern University’s Bouvé College of Health Sciences.

What is Warren Nighan Jr's net worth?

The estimated net worth of Warren Nighan Jr is at least $569.55 thousand as of January 16th, 2025. Jr owns 41,817 shares of AngioDynamics stock worth more than $569,548 as of December 4th. This net worth estimate does not reflect any other assets that Jr may own. Learn More about Warren Nighan Jr's net worth.

How do I contact Warren Nighan Jr?

The corporate mailing address for Jr and other AngioDynamics executives is 14 PLAZA DRIVE, LATHAM NY, 12110. AngioDynamics can also be reached via phone at (518) 795-1400 and via email at [email protected]. Learn More on Warren Nighan Jr's contact information.

Has Warren Nighan Jr been buying or selling shares of AngioDynamics?

Warren Nighan Jr has not been actively trading shares of AngioDynamics during the past quarter. Most recently, Warren Nighan, Jr. sold 4,060 shares of the business's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a transaction totalling $49,978.60. Following the completion of the sale, the senior vice president now directly owns 41,817 shares of the company's stock, valued at $514,767.27. Learn More on Warren Nighan Jr's trading history.

Who are AngioDynamics' active insiders?

AngioDynamics' insider roster includes Chad Campbell (SVP), Scott Centea (VP), James Clemmer (CEO), James Clemmer (CEO), Dave Helsel (SVP), Warren Jr (SVP), and Stephen Trowbridge (CFO). Learn More on AngioDynamics' active insiders.

Are insiders buying or selling shares of AngioDynamics?

During the last twelve months, AngioDynamics insiders bought shares 3 times. They purchased a total of 20,890 shares worth more than $239,532.40. During the last twelve months, insiders at the medical instruments supplier sold shares 1 times. They sold a total of 4,060 shares worth more than $49,978.60. The most recent insider tranaction occured on October, 21st when SVP Lawrence T Weiss bought 10,000 shares worth more than $118,100.00. Insiders at AngioDynamics own 6.0% of the company. Learn More about insider trades at AngioDynamics.

Information on this page was last updated on 10/21/2025.

Warren Nighan Jr Insider Trading History at AngioDynamics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2025Sell4,060$12.31$49,978.6041,817View SEC Filing Icon  
10/10/2024Buy100$6.08$608.0045,877View SEC Filing Icon  
10/7/2024Buy768$6.09$4,677.1245,777View SEC Filing Icon  
See Full Table

Warren Nighan Jr Buying and Selling Activity at AngioDynamics

This chart shows Warren Nighan Jr's buying and selling at AngioDynamics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AngioDynamics Company Overview

AngioDynamics logo
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
Read More

Today's Range

Now: $13.62
Low: $13.39
High: $13.99

50 Day Range

MA: $11.94
Low: $10.68
High: $13.62

2 Week Range

Now: $13.62
Low: $6.92
High: $13.99

Volume

489,938 shs

Average Volume

483,514 shs

Market Capitalization

$561.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49